Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB)After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Jun 25, 2015
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
The aim of this protocol is to study the appearance of the high grade AV conductive disorders at 12 months by monitoring for patients with a de novo LBBB after TAVI from an adapated algorithm to the risk and based on an early electrophysiological evaluation.
The recruitment of patients takes place in each cardiology department. The project is submitted to the Ethics Committee .
The patients are informed about this study by the investigator. After a reflection period and an answer to the possible questions, the patient is included. The informed consent is signed.
Every patient included wi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 year's old
- • Patient implanted by a percutaneous biological aortic valve according to the recommendations of the European society of cardiology according to the guidelines of ESC 2012
- • Life expectancy upper 1-year-old
- • Sinusal rhythm
- • Patient with a de novo LBBB post-TAVI persitent and observed beyond 24 hours after the procedure of TAVI.
- Exclusion Criteria:
- • Patient with a pacemaker pre-TAVI
- • Patient with LBBB pre-procedure
- • Pregnancy
- • Permanent atrial fibrillation
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Romain ESCHALIER
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials